Globeflex Capital L P boosted its position in United Therapeutics Corporation (NASDAQ:UTHR) by 18.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,100 shares of the biotechnology company’s stock after purchasing an additional 2,040 shares during the period. Globeflex Capital L P’s holdings in United Therapeutics Corporation were worth $1,699,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Piermont Capital Management Inc. purchased a new position in United Therapeutics Corporation in the 2nd quarter valued at approximately $401,000. M&T Bank Corp increased its stake in United Therapeutics Corporation by 8.8% in the 2nd quarter. M&T Bank Corp now owns 2,217 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 179 shares in the last quarter. California Public Employees Retirement System increased its stake in United Therapeutics Corporation by 4.5% in the 2nd quarter. California Public Employees Retirement System now owns 131,800 shares of the biotechnology company’s stock valued at $17,098,000 after purchasing an additional 5,700 shares in the last quarter. ETRADE Capital Management LLC increased its stake in United Therapeutics Corporation by 32.3% in the 2nd quarter. ETRADE Capital Management LLC now owns 2,161 shares of the biotechnology company’s stock valued at $280,000 after purchasing an additional 527 shares in the last quarter. Finally, FMR LLC increased its stake in United Therapeutics Corporation by 2.8% in the 2nd quarter. FMR LLC now owns 4,254,841 shares of the biotechnology company’s stock valued at $551,980,000 after purchasing an additional 116,062 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: “United Therapeutics Corporation (UTHR) Shares Bought by Globeflex Capital L P” was first reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.dailypolitical.com/2017/09/24/united-therapeutics-corporation-uthr-shares-bought-by-globeflex-capital-l-p.html.

Several research firms recently weighed in on UTHR. Jefferies Group LLC reaffirmed a “sell” rating and issued a $105.00 price objective on shares of United Therapeutics Corporation in a research note on Friday, July 14th. ValuEngine downgraded United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. UBS AG reaffirmed a “sell” rating and issued a $106.00 price objective on shares of United Therapeutics Corporation in a research note on Thursday, July 6th. BidaskClub raised United Therapeutics Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, June 9th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of United Therapeutics Corporation in a research note on Friday, September 8th. Six equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $134.50.

Shares of United Therapeutics Corporation (NASDAQ UTHR) traded down 0.74% during midday trading on Friday, reaching $114.60. The company’s stock had a trading volume of 372,309 shares. The stock’s 50 day moving average is $128.37 and its 200 day moving average is $129.08. The stock has a market capitalization of $4.98 billion, a PE ratio of 13.29 and a beta of 1.52. United Therapeutics Corporation has a 12 month low of $110.90 and a 12 month high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing the consensus estimate of $3.61 by ($4.86). United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The company had revenue of $444.60 million for the quarter, compared to analysts’ expectations of $391.53 million. During the same quarter in the prior year, the firm earned $4.42 earnings per share. The company’s revenue was up 7.8% on a year-over-year basis. On average, analysts forecast that United Therapeutics Corporation will post $10.09 EPS for the current fiscal year.

In other news, CEO Martine A. Rothblatt sold 1,274 shares of the business’s stock in a transaction on Thursday, September 21st. The shares were sold at an average price of $116.07, for a total transaction of $147,873.18. Following the transaction, the chief executive officer now directly owns 2,343 shares in the company, valued at approximately $271,952.01. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 1,237 shares of the business’s stock in a transaction on Thursday, June 29th. The shares were sold at an average price of $130.92, for a total transaction of $161,948.04. Following the transaction, the chief executive officer now owns 1,377 shares in the company, valued at $180,276.84. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,748 shares of company stock worth $2,806,738. 7.80% of the stock is currently owned by corporate insiders.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.